Board of Directors
in patients with end-stage renal disease
Phase 3 Completed Jan 2013; Pending NDA and MAA submissions.
Japan Phase 3 program completed by sublicensee (JT and Torii); Japanese NDA filed Jan 2013.
Management of serum phosphorus and
in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease ("NDD-CKD")
Phase 2 initiated Nov 2012; Ongoing.
Copyright © 2013 by Keryx Biopharmaceuticals, Inc.